skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 408  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Material Type:
Article 		Add to My Research

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

The Lancet (British edition), 2019-10, Vol.394 (10208), p.1551-1559 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)31344-3 ;PMID: 31522845

Full text available

Citations Cited by
2
Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography
Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography
Material Type:
Article 		Add to My Research

Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography

Archives of ophthalmology (1960), 2020-07, Vol.138 (7), p.740 [Peer Reviewed Journal]

Copyright American Medical Association Jul 2020 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2020.1376

Full text available

Citations Cited by
3
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
Material Type:
Article 		Add to My Research

Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data

American journal of ophthalmology, 2016-12, Vol.172, p.72-79 [Peer Reviewed Journal]

2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Dec 01, 2016 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2016.09.012 ;PMID: 27644589 ;CODEN: AJOPAA

Full text available

Citations Cited by
4
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
Material Type:
Article 		Add to My Research

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial

Archives of ophthalmology (1960), 2020-09, Vol.138 (9), p.935 [Peer Reviewed Journal]

Copyright American Medical Association Sep 2020 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2020.2443

Full text available

Citations Cited by
5
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
Material Type:
Article 		Add to My Research

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

Archives of ophthalmology (1960), 2020-09, Vol.138 (9), p.964 [Peer Reviewed Journal]

Copyright American Medical Association Sep 2020 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2020.2699

Full text available

Citations Cited by
6
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Material Type:
Article 		Add to My Research

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

Archives of ophthalmology (1960), 2019-04, Vol.137 (4), p.372 [Peer Reviewed Journal]

Copyright American Medical Association Apr 2019 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2018.6776

Full text available

Citations Cited by
7
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents
Material Type:
Article 		Add to My Research

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents

Archives of ophthalmology (1960), 2020-10, Vol.138 (10), p.1043 [Peer Reviewed Journal]

Copyright American Medical Association Oct 2020 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2020.3001

Full text available

Citations Cited by
8
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Material Type:
Article 		Add to My Research

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

British journal of ophthalmology, 2016-06, Vol.100 (6), p.787-795 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2015-307249 ;PMID: 26453639 ;CODEN: BJOPAL

Full text available

Citations Cited by
9
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
Material Type:
Article 		Add to My Research

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

Archives of ophthalmology (1960), 2020-09, Vol.138 (9), p.955 [Peer Reviewed Journal]

Copyright American Medical Association Sep 2020 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2020.2685

Full text available

Citations Cited by
10
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
Material Type:
Article 		Add to My Research

Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration

Cochrane database of systematic reviews, 2020-05, Vol.2020 (5), p.CD012208 [Peer Reviewed Journal]

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD012208.pub2 ;PMID: 32374423

Full text available

Citations Cited by
11
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Material Type:
Article 		Add to My Research

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches

International journal of molecular sciences, 2020-11, Vol.21 (21), p.8242 [Peer Reviewed Journal]

2020 by the authors. 2020 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms21218242 ;PMID: 33153227

Full text available

Citations Cited by
12
Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial
Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial
Material Type:
Article 		Add to My Research

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial

The Lancet (British edition), 2015-12, Vol.386 (10011), p.2395-2403 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 12, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(15)00345-1 ;PMID: 26431823 ;CODEN: LANCAO

Full text available

Citations Cited by
13
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
Material Type:
Article 		Add to My Research

Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV

British journal of ophthalmology, 2017-03, Vol.101 (3), p.353-359 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/2017This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2016-308668 ;PMID: 27215744

Full text available

Citations Cited by
14
Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
Material Type:
Article 		Add to My Research

Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

Cochrane database of systematic reviews, 2018-01, Vol.2018 (1), p.CD009734 [Peer Reviewed Journal]

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD009734.pub3 ;PMID: 29308602

Full text available

Citations Cited by
15
Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation
Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation
Material Type:
Article 		Add to My Research

Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation

Pharmaceutical research, 2018-12, Vol.35 (12), p.245-5, Article 245 [Peer Reviewed Journal]

The Author(s) 2018 ;COPYRIGHT 2018 Springer ;Pharmaceutical Research is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0724-8741 ;EISSN: 1573-904X ;DOI: 10.1007/s11095-018-2519-x ;PMID: 30374744

Full text available

Citations Cited by
16
Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides
Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides
Material Type:
Article 		Add to My Research

Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides

Investigative ophthalmology & visual science, 2017-05, Vol.58 (5), p.2578-2590 [Peer Reviewed Journal]

ISSN: 1552-5783 ;EISSN: 1552-5783 ;DOI: 10.1167/iovs.16-20072 ;PMID: 28494491

Full text available

Citations Cited by
17
Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial
Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial
Material Type:
Article 		Add to My Research

Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial

Archives of ophthalmology (1960), 2020-09, Vol.138 (9), p.945 [Peer Reviewed Journal]

Copyright American Medical Association Sep 2020 ;ISSN: 2168-6165 ;EISSN: 1538-3601 ;DOI: 10.1001/jamaophthalmol.2020.2457

Full text available

Citations Cited by
18
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
Material Type:
Article 		Add to My Research

A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration

British journal of ophthalmology, 2016-07, Vol.100 (7), p.914-917 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2015-306987 ;PMID: 26516125 ;CODEN: BJOPAL

Full text available

Citations Cited by
19
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
Material Type:
Article 		Add to My Research

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study

British journal of ophthalmology, 2016-12, Vol.100 (12), p.1623-1628 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2016 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2015-308166 ;PMID: 27030279 ;CODEN: BJOPAL

Full text available

Citations Cited by
20
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye
Material Type:
Article 		Add to My Research

Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye

Investigative ophthalmology & visual science, 2016-04, Vol.57 (4), p.1839-1846 [Peer Reviewed Journal]

ISSN: 1552-5783 ;EISSN: 1552-5783 ;DOI: 10.1167/iovs.15-18572 ;PMID: 27082298

Full text available

Citations Cited by

Results 1 - 20 of 408  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (399)

Refine My Results

Creation Date 

From To
Refine
  1. Before 2016  (52)
  2. 2016 To 2017  (184)
  3. 2018 To 2019  (97)
  4. 2020 To 2022  (64)
  5. After 2022  (12)
  6. More options open sub menu

Language 

  1. English  (401)
  2. Japanese  (79)
  3. French  (9)
  4. Portuguese  (4)
  5. Spanish  (4)
  6. Norwegian  (2)
  7. Turkish  (1)
  8. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait